FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 57257

Company■ Unclear/unknown

Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda

KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 12:00 UTC
LAST UPDATE2026-09-30 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Completed Phase 3 results for TAK-881 in primary immunodeficiency are posted without efficacy detail in the text.

Trial completion, outcome details absent
CATALYST TO WATCH

Full data readout or filing

MAIN RISK

Results content not summarized here

FULL DISPATCH

Sponsor: Takeda; Status: Completed; Conditions: Primary Immunodeficiency Diseases (PID); Interventions: TAK-881, HYQVIA; Enrollment: 65 (actual); First posted: 2023-03-06; Results posted: 2026-09-30; NCT: NCT05755035

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-09-30 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.